GSK Press Releases - EIN Presswire - Press Release Distribution Service

Published on October 26, 2011 - 09:10 GMT

GSK joins WIPO Re:Search open innovation platform as part of its commitment to tackling diseases of the developing world

Issued: Wednesday 26 October 2011, London UK GlaxoSmithKline (GSK) today announced it has joined WIPO Re:Search as part of its open innovation strategy to help accelerate the development of new and better treatments against neglected tropical diseases ( …

Distribution channels: Companies

Published on October 18, 2011 - 17:10 GMT

First results from ongoing Phase III trial show malaria vaccine candidate, RTS,S* reduces the risk of malaria by half in African ...

Issued: Tuesday 18 October 2011, London UK Half the world’s population is at risk of malaria which is responsible for close to 800,000 deaths each year, most of whom are children under five in sub-Saharan Africa First results from a large-scale Phase …

Distribution channels: Companies

Published on September 22, 2011 - 10:12 GMT

Lucozade to help drive Vodafone McLaren Mercedes performance

Issued: Thursday 22 September 2011, London, UK Ahead of this weekend’s Singapore Grand Prix, Lucozade – the UK’s leading sports and energy drink – today announces an innovative performance partnership with the Vodafone McLaren Mercedes Formula 1 …

Distribution channels: Companies

Published on September 15, 2011 - 08:11 GMT

GlaxoSmithKline (GSK) and McLaren Group announce innovative strategic partnership

Issued: Thursday 15 September 2011, London UK GlaxoSmithKline (GSK) today announced that it has formed a long term strategic partnership with McLaren Group. The partnership, which will run initially until 2016, brings together two UK companies focused …

Distribution channels: Companies

Published on September 12, 2011 - 13:13 GMT

GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease

Issued: Monday 12 September 2011, London UK and Cranbury, New Jersey, US GlaxoSmithKline (GSK) and Amicus Therapeutics today announced the first patient has commenced dosing in a Phase III global registration study (Study 012) to compare the safety and …

Distribution channels: Companies

Published on September 12, 2011 - 09:10 GMT

GSK gives update on agreement with World Health Organization to support de-worming of school age children in endemic countries

Issued: Monday 12 September 2011, London UK - First African countries, Togo and Rwanda, receive albendazole donations to scale-up school based de-worming programmes for children at risk of intestinal worms. Donations to go beyond Africa to include endemic …

Distribution channels: Companies

Published on September 7, 2011 - 16:12 GMT

Jens Eckstein named President of SR One, GSK’s venture healthcare group

Issued: Wednesday 07 September 2011, London UK Jens Eckstein has been named President of SR One, GSK’s independent healthcare venture organisation, effective 1 October. Jens will report to R&D Chairman Moncef Slaoui and be based in Boston. He …

Distribution channels: Companies

Published on August 15, 2011 - 12:12 GMT

GSK and Impax announce positive topline results of ASCEND-PD Phase III study of IPX066 in Advanced Parkinson’s disease

Issued: Monday 15 August 2011, London UK, Hayward, CA - IPX066 demonstrated statistically significant improvement over carbidopa-levodopa plus entacapone in reducing the percentage of “off time” during waking hours GlaxoSmithKline (GSK) and Impax …

Distribution channels: Companies

Published on August 10, 2011 - 14:11 GMT

GSK and Enigma Diagnostics announce collaboration on assay development and commercialisation of Enigma’s ML platform

Issued: Wednesday 10 August 2011, London UK GlaxoSmithKline (GSK) and Enigma Diagnostics Limited today announced that they have signed agreements for the supply and commercialisation on an exclusive basis of the Enigma ® ML system in Europe and other …

Distribution channels: Companies

Published on August 9, 2011 - 21:11 GMT

Regulatory Update: GSK and XenoPort submit supplemental New Drug Application to FDA for Horizant™ in postherpetic neuralgia

Issued: Tuesday 09 August 2011, London, UK, Research Triangle Park, NC & Santa Clara, CA GlaxoSmithKline (NYSE and LSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced today that a supplemental New Drug Application (sNDA) has been submitted to the …

Distribution channels: Companies

Published on August 3, 2011 - 14:11 GMT

Regulatory update – Stiefel, a GSK company, files NDA for tazarotene foam

Issued: Wednesday 03 August 2011, London UK Stiefel, a GSK company, announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), for tazarotene foam for the topical treatment of facial acne vulgaris …

Distribution channels: Companies

Published on July 21, 2011 - 15:12 GMT

GlaxoSmithKline European regulatory update on Pandemrix™

Issued: Thursday 21 July 2011, London UK GlaxoSmithKline (GSK) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an update to the product label for the H1N1 influenza vaccine …

Distribution channels: Companies

Published on July 14, 2011 - 11:10 GMT

GlaxoSmithKline and Human Genome Sciences receive European authorisation for Benlysta® (belimumab)

Issued: Thursday 14 July 2011, London UK, Rockville, Maryland, US GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the European Commission (EC) has granted marketing authorisation for Benlysta ® (belimumab) 10mg/ …

Distribution channels: Companies

Published on July 6, 2011 - 15:12 GMT

EU and US Regulatory Update - Votrient® (pazopanib)

Issued: Wednesday 06 July 2011, London UK and Philadelphia, PA GlaxoSmithKline (GSK) announced today that it has submitted a variation to the Marketing Authorisation Application to the European Medicines Agency for Votrient (pazopanib) for the …

Distribution channels: Companies

Published on July 4, 2011 - 13:10 GMT

London 2012 partner, GlaxoSmithKline, shares scientific expertise with World Anti-Doping Agency to help fight against abuse of ...

Issued: Monday 04 July 2011, London UK London 2012 partner GlaxoSmithKline (GSK) today signed a long-term agreement with the World Anti-Doping Agency (WADA) that will help the agency create early detection methods for medicines that have …

Distribution channels: Companies

Published on July 1, 2011 - 13:10 GMT

GlaxoSmithKline receives new approval for Rotarix and significant new indication for Lamictal® (lamotrigine) in Japan

Issued: Friday 01 July 2011, London UK – GSK’s rotavirus vaccine approved for use in babies for the prevention of rotavirus gastroenteritis – Lamotrigine becomes the first treatment to be approved in Japan for adult bipolar disorder …

Distribution channels: Companies

Published on June 13, 2011 - 07:10 GMT

GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine)

Issued: Monday 13 June 2011, London, UK, Research Triangle Park, NC & Mississauga, ON GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) announced today that the U.S. Food and Drug Administration …

Distribution channels: Companies

Published on June 6, 2011 - 16:12 GMT

GlaxoSmithKline’s pazopanib improved progression free survival in adults with certain soft tissue sarcomas

Issued: Saturday 04 June 2011, Chicago, Illinois Results of the PALETTE (PAzopanib ExpLorEd in SofT-Tissue Sarcoma) study presented at the 2011 Annual Meeting of the American Society for Clinical Oncology demonstrated a statistically significant …

Distribution channels: Companies

Published on June 6, 2011 - 10:10 GMT

Millions of children in the world’s poorest countries could receive vaccination against diarrhoeal disease under new offer made by ...

Issued: Monday 06 June 2011, London, UK – Offer to supply up to 125 million doses of Rotarix TM over five years to developing countries at approximate 95% reduction to Western market price – Rotavirus causes 500,000 childhood …

Distribution channels: Companies

Published on June 4, 2011 - 09:10 GMT

GlaxoSmithKline’s pazopanib improved progression free survival in adults with certain soft tissue sarcomas

Issued: Saturday 04 June 2011, Chicago, Illinois Results of the PALETTE (PAzopanib ExpLorEd in SofT-Tissue Sarcoma) study presented at the 2011 Annual Meeting of the American Society for Clinical Oncology demonstrated a statistically significant …

Distribution channels: Companies